Table 2.
Pretreatment characteristics by QoL completion
| Pretreatment characteristic | QoL (n=166) | No QoL (n=52) | χ2 test P value | |
|---|---|---|---|---|
| Gender | Male | 120 (72%) | 34 (65%) | .34 |
| Female | 46 (28%) | 18 (35%) | ||
| Race | White | 113 (68%) | 31 (60%) | White vs. non-white |
| Hispanic | 4 (2%) | 3 (8%) | .26 | |
| Black | 48 (29%) | 17 (33%) | ||
| Asian/Pacific | 1 (1%) | 1 (2%) | ||
| Weight loss | >10% | 62 (37%) | 29 (56%) | .02* |
| <10% | 104 (63%) | 23 (44%) | ||
| Age | Median | 64 | 63 | .16 |
| Range | 43–81 | 37–78 | ||
| KPS | 60–80 | 65 (39%) | 33 (63%) | .002* |
| 90–100 | 101 (61%) | 19 (37%) | ||
| Lesion size | <5 cm | 79 (48%) | 25 (48%) | .95 |
| >5 cm | 87 (52%) | 27 (52%) | ||
| Histology | Squamous | 138 (83%) | 47 (90%) | .20 |
| Adenocarcinoma | 28 (17%) | 5 (10%) | ||
*
P values significant at the.05 level.
Abbreviations: KPS = Karnofsky performance status; QoL = quality of life.